Autres langues Cingulate Inc.

Actions

CING

US17248W2044

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
0,32 ^USD	-45,21%		-44,79%	-95,82%

21/05	La FDA autorise Cingulate à déposer une demande d'autorisation de mise en marché pour le CTx-1301 dans le traitement du TDAH	CI
08/05	Cingulate Inc. annonce ses résultats pour le premier trimestre terminé le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds	28/06
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event	25/06
Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance	25/06
Cingulate : Failure to Satisfy Listing Rule Form 8 K	19/06
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD	21/05
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD	21/05
Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update	08/05
Certain Pre-Funded Warrants of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05
Certain Warrants of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05
Certain Stock Options of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05
Certain Common Stock of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access	30/04
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024	16/04
Cingulate Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Cingulate Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update	01/04
Cingulate to Participate in Benzinga All Live Access Event	19/03
Cingulate to Attend DCAT Week 2024 in New York City	06/03
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors	13/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cingulate Inc.

Actions

CING

US17248W2044

Autres langues

Filtres